GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth

GSK PLC (LSE:GSK, NYSE:GSK) got a grudging nod from Citi on Thursday, as the investment bank lifted its earnings forecasts for the drugmaker but stopped well short of a buy call. The shares edged up 0.31% to 1,922p as Citi kept its 'neutral' rating, tweaking its model after GSK's Accelerate Growth event and second-quarter results.

Proactive Investors • 12 hours ago

Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences

President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scientific basis and is unlikely to get off the ground.

CNBC • Aug 11, 2026

GSK India first-quarter profit rises on steady vaccine demand

Vaccine maker GlaxoSmithKline Pharmaceuticals reported a 15.7% rise in first-quarter profit on Monday, aided by stable ​demand across its vaccine and drug portfolio, including ‌respiratory and specialty medicines.

Reuters • Aug 3, 2026

GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal

British biotech firm Relation Therapeutics said on Wednesday it ​had entered into a research ‌collaboration with GSK worth up to $110 million to generate human cellular ​datasets and train AI ​models for identifying potential new ⁠drug targets.

Reuters • Jul 30, 2026

Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US

A federal appeals court on Thursday revived portions of nationwide litigation in which consumers ‌accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars of over-the-counter decongestants that didn't work.

Reuters • Jul 30, 2026

GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan

GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.

Zacks Investment Research • Jul 29, 2026

GSK to invest £400 million in Britain over 3 years as it ramps up R&D efforts

British drugmaker GSK said on Tuesday that it will invest £400 million ($531.12 million) over 3 years ​in the country, including a new R&D ‌center in Cambridge as part of its plans to develop medicines faster under new CEO Luke Miels.

Reuters • Jul 28, 2026

GSK beats second-quarter profit estimates, launches $2.52 billion cost savings drive

GSK on Tuesday ​beat second-quarter profit ‌expectations and launched a £1.9 ​billion ($2.52 billion) ​cost savings drive ⁠as the ​British drugmaker ​seeks to ramp up its development ​pipeline ​to support its long-term ‌sales ⁠ambition.

Reuters • Jul 28, 2026

GSK, Hansoh's cancer drug meets main goal of bone cancer trial

GSK on ​Tuesday said ‌partner Hansoh Pharmaceutical's ​experimental ​drug Ris-Rez met ⁠its main ​goal ​of keeping an aggressive bone ​cancer ​from worsening in ‌a ⁠late-stage trial, just weeks ​after ​it ⁠succeeded in ​another ​advanced ⁠study.

Reuters • Jul 28, 2026

GSK hits three-month high as vaccines help earnings top forecasts

GSK PLC (LSE:GSK, NYSE:GSK) shares jumped to a three-month high after the drugmaker beat second-quarter expectations across its main measures and accelerated investment in its pipeline. Revenue rose 5% to £8.41 billion, ahead of the £8.25 billion City consensus.

Proactive Investors • Jul 28, 2026